Previous Article | Next Article ![]()
Journal of Virology, December 2000, p. 11919-11927, Vol. 74, No. 24
Institut für Klinische und Molekulare Virologie der
Universität Erlangen-Nürnberg1 and
Pathologisch-Anatomisches Institut,4
91054 Erlangen, Germany; Biomedical Primate Research Center,
2288GJ Rijswijk, The Netherlands2; and
GenVec, Inc., Gaithersburg, Maryland
208783
Received 26 June 2000/Accepted 25 September 2000
Apoptosis of infected cells is an important host defense mechanism,
and many viruses have exploited antiapoptotic proteins that interfere with crucial cellular pathways. Viral FLICE inhibitory proteins (vFLIPs) are encoded by rhadinoviruses like herpesvirus saimiri, the related Kaposi's sarcoma-associated herpesvirus-human herpesvirus 8 (KSHV/HHV8), and the poxvirus responsible for molluscum contagiosum. The vFLIPs can block the interaction of the death receptor-adapter complex with the cellular effector FLICE
(caspase-8), and this prevents the initiation of the downstream
caspase cascade. KSHV/HHV8 vFLIP overexpression can confer
resistance to T-cell-mediated apoptosis and acts as a tumor
progression factor in a murine B-cell lymphoma model. To analyze the
function of herpesvirus vFLIPs in the genetic background of the virus
and in a model for viral pathogenesis, we deleted the vFLIP gene (open
reading frame 71) from the genome of herpesvirus saimiri strain C488.
The viral deletion mutant was viable and replicated like the wild-type
virus. An antiapoptotic effect could be attributed to the
vFLIP gene, but we also show that the vFLIP gene of herpesvirus saimiri
is dispensable for viral transformation of T cells in vitro and for pathogenicity in cottontop tamarins in vivo.
Viruses utilize various strategies
that relate to apoptosis of host cells or attacking effector
cells of the immune system. Since the induction of programmed cell
death in cells infected with various pathogens is an important and
common host defense mechanism, many viruses have evolved proteins to
evade this protective mechanism. On the other hand, apoptosis
is used by some viruses to promote the release of progeny from infected
cells (47).
Open reading frame 71 (ORF71) of the oncogenic herpesvirus saimiri
(saimirine herpesvirus 2) encodes a putative antiapoptotic protein that is homologous to a family of cellular and viral inhibitory proteins which interfere with apoptosis signaled through the
death receptor Fas-CD95 and the tumor necrosis factor receptor 1 (TNFR-1) (5, 30, 31, 54).
The binding of a specific ligand to death receptors expressed on
eukaryotic cells induces multimerization of the receptor complex, and
this clustering recruits adapter molecules like the FADD
(Fas-associated death domain) protein or the TNFR-associated death
domain protein via interactions between the death domain of the
receptor and the death domain of the adapter. The formation of the
death receptor-adapter complex recruits the upstream caspase-8 (FLICE) by interaction between the death effector domain (DED) of the
adapter protein and the DED of the caspase. Together they form the
death-inducing signaling complex, and caspase-8 is activated by
proteolytic autocleavage, which initiates the downstream caspase cascade and results in apoptosis (3, 24).
Viral FLICE inhibitory proteins (vFLIPs) are found in the poxvirus
responsible for molluscum contagiosum and in most of the Gammaherpesviridae of the genus Rhadinovirus,
namely the Kaposi's sarcoma (KS)-associated herpesvirus-human
herpesvirus 8 (KSHV/HHV8), rhesus rhadinovirus (RRV) (2,
50), herpesvirus saimiri, equine herpesvirus 2 (30),
and bovine herpesvirus 4 (55). The vFLIPs contain two DEDs
and have been shown to block the interaction of a death
receptor-adapter complex like Fas-FADD with the cellular effector
FLICE (caspase-8) and prevent its autoactivation (5, 30,
54). A cellular homolog to the vFLIPs has also been identified, although it occurs in two forms: the short cellular form, cFLIP(S), contains two DEDs and acts at the same level as the vFLIPs by preventing FADD-FLICE interaction; the long form, cFLIP(L), resembles the caspase-8 structure with two DEDs plus a caspase
domain. However, the active site of the protease domain is mutated.
cFLIP(L) can also interact with the autoactivation step of
caspase-8 (31).
Overexpression of KSHV/HHV8 vFLIP by retroviral transduction of the
murine B cell line A20 has been shown to confer resistance against
death receptor-mediated apoptosis. It promotes clonal outgrowth
in the presence of death stimuli, and caspase activation in the
vFLIP-A20 transductants is inhibited. When transferred into syngeneic
or semiallogeneic immune competent mice, the vFLIP-transduced B cells
induced significantly more and faster-growing B-cell tumors than the
mock-transduced line. This difference was not evident in immune
response-compromised mice, suggesting that vFLIP is a tumor progression
factor that can offer protection from T-cell-mediated apoptosis
(15). Similarly, the cFLIP has been shown to prevent tumor
rejection in a different mouse model, also presumably by escape from
cytotoxic T-cell-mediated apoptosis, and lead to tumor progression (40). Additional evidence points to a modulation of the NF- Studying the vFLIP function of herpesvirus saimiri provides (i) a
permissive cell culture system that allows the construction of
recombinant viruses, (ii) in vitro lymphocyte transformation assays in
human and simian T cells, and (iii) a meaningful and stringent animal
model for pathogenesis in common marmosets or cottontop tamarins. A
previous study argues for the function of the herpesvirus saimiri vFLIP
gene, since it demonstrates an antiapoptotic effect during
the lytic infection of owl monkey kidney (OMK) cells (54).
Although protection from apoptosis was evident in infected cells, the data is weakened by the fact that herpesvirus saimiri contains at least one other antiapoptotic protein, a viral
Bcl-2 homolog that is functional in in vitro models (11,
43). Thus, vFLIP function has been proven neither in the normal
genetic background of the virus nor in a model for viral pathogenesis.
Therefore, we generated a vFLIP deletion mutant by removing the vFLIP
gene (ORF71) from the genome of herpesvirus saimiri strain C488. The
C488 Cell culture and virus propagation.
OMK cells (ATCC
CRL1556), cultivated in Dulbecco's modified Eagle medium supplemented
with glutamine (350 µg/ml), gentamicin (100 µg/ml), and 10%
heat-inactivated fetal calf serum, were used for the propagation of
herpesvirus saimiri. Virus stocks were generated by the infection of
confluent OMK cells seeded in 175-cm2 tissue culture flasks
at a low multiplicity of infection. When lysis was complete,
supernatants were cleared from the cellular debris by centrifugation at
2000 × g for 15 min, and cell-free supernatants were
stored at Construction of the viral deletion mutant C488
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Herpesvirus Saimiri vFLIP Provides an Antiapoptotic
Function but Is Not Essential for Viral Replication,
Transformation, or Pathogenicity
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
B pathway by the interaction of vFLIPs with signaling proteins (8). However, all these observations are from in
vitro overexpression of recombinant proteins (5, 30) or
transplantation of tumor cell transfectants into mice (15).
FLIP deletion mutant was replication competent, and we
demonstrate that the antiapoptotic effect is lost after deletion of vFLIP. However, we also show that the vFLIP gene of herpesvirus saimiri is dispensable for the viral transformation of T
cells in vitro and for pathogenicity in cottontop tamarins in vivo.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
80°C. Peripheral blood mononuclear cells (PBMC) of
Callithrix jacchus and human umbilical cord blood lymphocytes (CBL) were isolated by density gradient centrifugation. The
cells were cultivated in lymphocyte growth medium (LGM) (45% RPMI 1640 medium, 45% Panserin [Pansystems, Aidenbuch, Germany], 10% fetal
calf serum [Pansystems], gentamicin [100 µg/ml], and glutamine
[350 µg/ml]). LGM for human CBL was supplemented with 100 U of
recombinant human interleukin-2 (IL-2) (aldesleukin; ProleukinR; Chiron, Ratingen, Germany) per ml or 20 U of
human IL-2 (Roche Diagnostics, Mannheim-Penzberg, Germany) per ml.
FLIP.
ORF71
was deleted from the herpesvirus saimiri strain C488 genome by a
cosmid-based approach. All cloning procedures were performed by
standard methods. A PacI fragment including most of ORF71
was subcloned from cosmid 40 into pNEB193 (New England Biolabs). Most
of the ORF71 gene, including the two DEDs, was deleted by digestion
with BclI-SalI. A double-stranded oligonucleotide adapter was designed from the oligonucleotides
5'-GATCGTTTAAACGTTAATTAATCGA-3' and
5'-TCGATCGATTAATTAACGTTTAAAC-3'. This
adapter contained an internal PacI site (bold), as well as
BclI-and SalI-compatible 5' overhangs
(underlined) at the ends. It was inserted into the BclI-SalI-digested pNEB193-Pac to replace the
deleted ORF71 segment (Fig. 1A). The
altered PacI fragment encompassing the deleted ORF71 gene
segment was reinserted into the PacI-digested cosmid 40, resulting in cosmid 40
FLIP. The correct insertion was verified by
sequencing. Recombinant virus was generated by liposome-mediated cotransfection of a set of overlapping cosmids, including cosmid 40
FLIP, into permissive OMK cells (Fig. 1B). The cosmids were linearized before transfection by restriction with NotI;
this also removed the pWE15 cloning vector, since two NotI
sites flank the BamHI site that was used to clone the viral
DNA. Virus-containing supernatant from completely lysed cultures was
harvested by centrifugation, and the pelleted virions were lysed in 100 µl of PCR buffer containing 100 µg of proteinase K (Roche
Diagnostics) per ml and 0.5% Tween 20 for 1 h at 56°C; then the
proteinase K was heat inactivated for 15 min at 95°C. An aliquot of 2 to 4 µl was used for PCR analysis.

View larger version (27K):
[in a new window]
FIG. 1.
Construction of the recombinant viruses
herpesvirus saimiri C488
FLIP, C488EGFP, and C488
FLIP-EGFP.
The vFLIP encoding ORF71 of herpesvirus saimiri C488 was deleted from
the right terminal cosmid 40. (A) A PacI fragment was
subcloned into vector pNEB193, and most of the ORF71 gene was deleted
by digestion with BclI and SalI and insertion of
an adapter containing a PacI site. Then the altered
PacI fragment from pNEB193 was reinserted into
PacI-digested cosmid 40 to generate the cosmid 40
FLIP.
(B) Recombinant virus was generated by the cotransfection of
overlapping linearized cosmids 331 or 331EGFP, 261, 291, 336, and 40 or
40
FLIP.
Construction of C488EGFP recombinant. The enhanced green fluorescent protein (EGFP) gene was PCR amplified from plasmid pEGFP-C1 (Clontech). PCR mixtures (50 µl each) contained 2 µl of template DNA, 0.2 µM each deoxynucleoside triphosphates (dNTP), 10 µM each primer, and 5 U of Pfu polymerase (Stratagene) in 1× Pfu reaction buffer. The primers 5'-GGGCGCGCCGAATGCAGTGAAAAAAATGC-3' and 5'-GGCGCGCCATTAATAGTAATCAATTACG-3' were used. After a 1-min initial denaturation step at 95°C, 25 cycles of 10 s at 95°C, 20 s at 55°C, and 3 min at 70°C were performed in an MJ Research PTC-200 thermal cycler, followed by a 4-min final extension step at 70°C. The PCR fragment was then subcloned into the single SwaI site of cosmid 331 located just upstream of the DHFR gene (ORF2) in a noncoding region. The construct was analyzed by sequencing, and expression of the EGFP was verified by transfection into OMK cells and fluorescence microscopy.
DNA sequence analysis. Nucleotide sequences were determined with an ABI 377A automated sequencer (Applied Biosystems) using the Dye-Deoxy Terminator Sequencing kit according to the manufacturer's instructions (Perkin-Elmer). DNA sequence evaluation was done with XBAP software (10).
Virus stocks and replication studies.
For virus titration,
OMK cells were grown in 48-well plates (Nalgene Nunc International,
Roskilde, Denmark) and infected with serial ten-fold dilutions
(10
3 to 10
7) of herpesvirus saimiri C488,
C488
Flip, and the respective EGFP variants in 400 µl of
Dulbecco's modified Eagle medium with supplements. A dilution step was
defined as positive if the cells in at least 4 of 8 wells were
completely lysed. The virus replication kinetics was determined by the
infection of OMK cells (3 × 105 cells seeded in a
25-cm2 flask 2 days before infection) with 104
tissue culture infectious particles (TCIP) in 10 ml of medium. The
titers of virus-containing supernatant taken on subsequent days were
determined by limiting dilution as described above.
In vitro transformation of lymphocytes.
Lymphocytes were
expanded after isolation for 2 to 3 days by stimulation with 0.5 to 1 µg of phytohemagglutinin A (Murex, Großburgwedel, Germany) per ml.
Between 3 × 106 and 5 × 106 cells
were infected with 1 ml of herpesvirus saimiri C488 or mutant virus
C488
FLIP containing supernatants (titer, >106 TCIP/ml)
and cultivated in LGM as described above. The transformation of the
resulting T-cell lines was assessed microscopically and by the
observation of accelerated growth.
Experimental infection of common marmosets.
In vivo
oncogenicity of the herpesvirus saimiri C488 recombinants was assayed
by experimental infection of Saguinus oedipus tamarins. The
study was approved by the Institutional Animal Care and Use Committee
and was performed according to governmental regulations with
purpose-bred, healthy, adult cottontop tamarins at the Biomedical
Primate Research Center (Rijswijk, The Netherlands). Two animals were
infected with the experimental virus C488
FLIP, and only one animal
was infected with the wild-type control virus C488. Since cottontop
tamarins are an endangered and protected species, larger numbers of
animals could not be justified from an ethical point of view. Two
animals per experimental virus are considered necessary to obtain a
meaningful result in a primate experiment, and this number is usually
used in published studies. Since the wild-type virus C488 is highly
pathogenic and generally causes lymphoma in all infected animals
(C. jacchus or S. oedipus) (17, 35,
36), only one animal was allowed to obtain control tissues and
cell lines. The animals were each intravenously injected with 1 ml of
cell-free virus containing supernatant from infected OMK cultures
containing 106 TCIP of virus. They were housed in separate
cages and received a standard monkey diet and drinking water ad
libitum. Blood samples were taken prior to infection, at weekly
intervals, and before necropsy to expand T lymphoma cells and reisolate
virus by cocultivation on OMK cells. The animals were euthanized as
soon as illness became evident. Tissues were fixed in formalin and
stained with hematoxylin and eosin and for immunohistochemistry
additionally with antibodies specific for CD3 (Dako, Hamburg, Germany)
and CD20 (Dako).
Detection of viral DNA. The status of viral DNA in the transformed cell lines was analyzed by PCR and Southern blotting. PCR analysis was carried out in 25-µl reaction mixtures, each containing 2 µl of template DNA, 0.2 µM each dNTP, 10 µM each primer, and 2.5 U of AmpliTaq in 1× AmpliTaq buffer (Perkin-Elmer). PCR conditions were as follows: a 5-min denaturation at 95°C; 29 cycles of 30 s at 95°C, 30 s at 56°C, and 1 min at 70°C; a 4-min extension at 70°C; and a 4°C hold. The following primer pairs specific for the respective ORFs were used for the analysis: StpC/Tip (TR1 5'-GTAGTAAACTAAGAGCAAAGCAAGC-3' and TR2 5'-GTACAAGCTGTTCAAGTTTGTTAGC-3'), ORF3 (5'-CACAACACTGGTATGTACCAATG-3' and 5'-CTGTGGAGGTAATGCAGATAC-3'), ORF75 (5'-TGGCTGCTAACAGGCATGG-3' and 5'-AGCACGTTGCCCGAGATTG-3'), and ORF71/FLIP (5'-GGCGCGCCTCGAAATTCTGTAAATGGAC-3' and 5'-ACAGAAAGAGACACAAGAG-3').
DNA for Southern blotting was prepared by the addition of 400 µl of extraction buffer (100 mM NaCl, 10 mM Tris-HCl, 25 mM EDTA, 0.5% sodium dodecyl sulfate; proteinase K was added to a final concentration of 1 mg/ml) to 5 × 107 cells. After an overnight incubation at 56°C, the solution was digested with 40 µl of RNase A (5 mg/ml) at 37°C for 30 min. The DNA was extracted with buffer-saturated phenol:chloroform:isoamyl-alcohol (25:24:1), and then a one-half volume of ammonium acetate (7.5 M) was added to the aqueous phase, and the DNA was precipitated with 2 volumes of ethanol. After centrifugation, the pellet was washed with 70% (vol/vol) ethanol, dried briefly, and resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA). A total of 20 µg of cellular DNA was digested with SstI or PstI. The DNA fragments were size fractionated by electrophoresis through a 1% agarose gel. The DNA was then transferred to a nylon membrane (Hybond N; Amersham) and hybridized with a 32P-labeled DNA fragment. This 1.9-kb probe specific for ORF71 and -72 was amplified by PCR from cosmid 40 (primers, 5'-TGCGTTAGACAAATATCCC-3' and 5'-CTAAAAATGCAGCATCGTCACC-3'; conditions were as above). The DNA fragment was purified from a 1% agarose gel (Qiaquick Gel Extraction kit; Qiagen, Hilden, Germany), and random labeling with [
-32P]dATP was performed (20).
RNA and cDNA analysis. Total cellular RNA was prepared by the acidic phenol extraction method (9). Five micrograms of RNA was treated with RNase-free DNase I (Roche Diagnostics) in 1× DNAse I buffer for 30 min, followed by heat inactivation at 70°C for 10 min. Then, first-strand cDNA was synthesized with Superscript II reverse transcriptase (Gibco BRL): the RNA was incubated with 500 ng of random hexamer primers for 10 min at 70°C. After a short incubation on ice, 8 µl of the reaction mixture (4 µl of 5× first-strand buffer, 2 µl of 0.1 M dithiothreitol, 1 µl of 10 mM dNTPs, and 1 µl of Superscript II) was added, and the synthesis of the cDNA was started (10 min at 25°C and 50 min at 37°C). The enzyme was heat inactivated at 70°C for 15 min. RNA complementary to the cDNA was removed by the addition of 1 U of RNase H (MBI Fermentas) and incubation for 20 min at 37°C. An identical sample was prepared in parallel where the reverse transcriptase was omitted from the reaction mixture (as a control sample). A total of 2 µl of the reaction mixture was used for reverse transcription (RT)-PCR analysis. PCR conditions were as follows: a 5-min initial denaturation at 95°C; 39 cycles of 20 s at 95°C, 30 s at 52°C, and 1 min at 70°C; a 4-min final extension at 70°C; and a 4°C hold. Primers utilized were specific for the ORF71/FLIP (as above) and ß-actin (5'-CGGGAAATCGTGCGTGACAT-3' and 5'-GAACTTTGGGGGATGCTCGC-3').
Flow cytometry.
Transformed human and simian T cells were
analyzed by flow cytometry with antibodies for B- and T-cell surface
epitopes on a FACS-Calibur flow cytometer (Becton Dickinson). The
directly labeled monoclonal antibodies (MAbs) (Cy-Chrome or
phycoerythrin conjugated) were specific against CD2 (RPA-2.10;
PharMingen, Heidelberg, Germany), CD3
(SP34; PharMingen), CD3
(Leu-4; Becton Dickinson), CD4 (Leu-3a SK3; Becton Dickinson), CD8
(RPA-T8; PharMingen), CD20 (Leu16 L27; Becton Dickinson), HLA-DR (L243;
Becton Dickinson), CD80 (L307.4; PharMingen), and CD86 (IT2.2;
PharMingen). Directly labeled isotype-matched control MAbs were used
(Becton Dickinson and PharMingen). CD95 surface expression was detected
with a MAb directed to CD95 (DX2; PharMingen) and a secondary
fluorescein isothiocyanate-labeled goat anti-mouse immunoglobin G
F(ab')2 fragment (Dianova, Hamburg, Germany).
Immunofluorescence.
A total of 104 OMK cells
were seeded in four-well chamber slides (Nalgene Nunc International)
and infected with the EGFP variants of C488 and C488
FLIP. After
24 h, the cells were overinfected with recombinant adenovirus
expressing the soluble Fas ligand (Ad-FasL) (7), or 50 µM
menadione was added and the cells were incubated for 4 or 8 h at
37°C and fixed with 4% paraformaldehyde (30 min at room
temperature). To visualize nuclei and DNA, the cells were stained by
the addition of 1 µg of Hoechst-33342 dye (Sigma) per ml. The
apoptotic cells were viewed under a Zeiss Axiovert fluorescence
microscope at a magnification of ×630.
Induction of apoptosis and determination of cell
death.
A total of 104 OMK cells were grown in
flat-bottomed 96-well plates (Nalgene Nunc International) overnight and
infected with 5 × 104 to 10 × 104
TCIP of the recombinant viruses C488EGFP and C488
FLIP-EGFP
(multiplicity of infection, 5 to 10). After 24 h the cells were
superinfected with recombinant adenovirus (Ad) Ad-FasL (0.5 × 106 PFU) or the
-GAL gene (Ad-Z) as a control (GenVec,
Inc., Gaithersburg, Md.). After incubation for 4 h at 37°C, cell
death was quantified by an enzyme-linked immunosorbent assay (ELISA)
for the detection of histones bound to fragmented DNA released into the
cytoplasm of apoptotic cells (Cell Death Detection kit; Roche
Molecular Biochemicals, Mannheim, Germany). Cytoplasmatic extracts were normalized to their total protein content that was determined by the
BCA-Assay (Pierce, Inc., Rockford, Ill.). Specific protection from
apoptosis was calculated as follows: 10,000 × (optical
density/protein [µg/ml]). Uninfected cells treated with Ad-FasL
were assigned a value of 100% apoptosis.
| |
RESULTS |
|---|
|
|
|---|
Construction of recombinant viruses.
The herpesvirus
saimiri ORF71 encoding the vFLIP was deleted by a cosmid-based
approach that allows the construction of recombinant viruses without
contaminating wild-type virus. Previously, we had subcloned the genome
of herpesvirus saimiri into overlapping cosmids (18). The
right-terminal cosmid 40 was selected for the deletion of ORF71. In the
genome of herpesvirus saimiri strain C488, the methionine start codon
of ORF71 is located directly adjacent to the ochre stop
codon terminating the ORF72 encoding the vCyclin. The ORF71 contains a
PacI restriction site 72 bp downstream of the first ATG
codon. A second PacI site is located at a distance of 2.15 kb in the noncoding region between ORF70 (encoding a thymidylate
synthase) and ORF71. This 2.15-kb PacI restriction fragment
encompassing most of vFLIP was subcloned from cosmid 40 into plasmid
pNEB193 to generate pNEB193-Pac. The region including the two DEDs of
vFLIP was removed by restriction of pNEB193-Pac with BclI
and SalI and replaced by an oligonucleotide adapter
containing a PacI site. The modified PacI
fragment was then reinserted into cosmid 40 to generate cosmid
40
FLIP (Fig. 1A). The correct insertion was verified by restriction
mapping and sequencing. A human cytomegalovirus-promoter driven EGFP
expression cassette was inserted into a noncoding region of cosmid 331 to generate cosmid 331EGFP. Recombinant viruses were then constructed by cotransfection of linearized cosmids into OMK cells. The recombinant virus C488
FLIP was generated from cosmids 331, 261, 291, 336, and
40
FLIP. We also designed an EGFP-expressing recombinant vFLIP deletion virus and a corresponding control virus. The recombinant EGFP-expressing vFLIP deletion virus C488
FLIP-EGFP was generated from cosmids 331EGFP, 261, 291, 336, and 40
FLIP; the recombinant EGFP-expressing control virus C488EGFP was generated from cosmids 331EGFP, 261, 291, 336, and 40 (Fig. 1B).
Replication of recombinant viruses.
Recombinant viruses were
obtained from cosmid cotransfection, demonstrating that the vFLIP gene
of herpesvirus saimiri is not essential for lytic
replication in OMK cells. No differences in plaque size or morphology
in OMK cells were notable (data not shown). Lytic viral replication of
C488
FLIP on OMK cells was compared to that of C488. Endpoint titers
of both viruses were in the range of 106 to 107
TCIP per ml of supernatant from several independent cultures. The
kinetics of viral replication was then compared by infection of
OMK cultures with 104 TCIP and by titration of supernatant
taken from successive days. There was no apparent difference between
the viruses, lysis was complete after 7 days, and similar endpoint
titers of 107 were observed (Fig.
2).
|
Transformation of human and simian T cells in vitro.
Herpesvirus saimiri is able to transform human and simian T cells to
permanent antigen-independent growth in vitro (6). Human CBL
(13 donors) and PBMC from C. jacchus (5 donors) and S. oedipus (10 donors) were infected with C488 and C488
FLIP in parallel, and the proliferation of the cells was compared to that in
uninfected controls. After 4 to 6 weeks of culture, the control cells
had stopped growing. Both the deletion mutant virus C488
FLIP as well
as the wild-type virus C488 transformed the T cells. The data are
summarized in Table 1. The transformed T
cell lines were analyzed by PCR and Southern blot analysis, and the
specific viral genotype present in the cells was confirmed.
Proliferation tests performed with the established T-cell lines showed
no detectable difference (data not shown). Thus, the vFLIP is not
essential for replication and T-cell transformation in vitro.
|
Pathogenicity in cottontop tamarins.
One putative function of
vFLIP is the escape of transformed cells from immune surveillance by
interference with cytotoxic T-cell-mediated apoptosis, which is
difficult to study in vitro. Herpesvirus saimiri C488 is able to
induce T-cell lymphoma in vivo in several species of New World
primates. In vitro transformation is linked to pathogenicity in vivo
for most published viral deletion mutants. However, there are reports
where efficient in vitro transformation was observed but where the
recombinant virus turned out to be apathogenic or less pathogenic than
wild-type virus in vivo (16, 28, 38). The relevance of the
vFLIP gene for the development of T-cell lymphoma was studied in
cottontop tamarins (S. oedipus). Two animals were infected
intravenously with the deletion mutant virus C488
FLIP (animals B237
and R213) and one was infected with the wild-type virus C488 carrying
an intact vFLIP (animal B236). All animals developed disease between
day 14 and 15 and were euthanized (Table 1). Necropsy was performed,
and macroscopic findings were consistent with the typical
lymphoproliferative disease induced by herpesvirus saimiri. Enlarged
lymph nodes and spleen and infiltrations in various organs were
recognizable. Immunohistochemistry revealed infiltrations of
CD3+ blast-like lymphoid cells in various tissues of all
three animals (Fig. 3A). Infiltration of
virus-transformed T cells was widespread in the different organs or
tissues, and the morphology of infiltrations was similar in the
wild-type- and deletion virus-infected animals. Continuously growing
T-cell lines from thymus, spleen, liver, kidney, and lymph nodes were
established. The cultures grew stably over an observation period of
more than 10 months, and there was no difference detectable in the
proliferation of the cell lines transformed by the recombinant or the
wild-type viruses. DNA from the transformed T-cell cultures established
from the infected animals was used to confirm the presence of the
specific viral genome by Southern blotting and PCR (Fig. 3B and C).
Thus, the vFLIP gene is also dispensable for the capacity of
herpesvirus saimiri to induce T-cell lymphoma in vivo.
|
Expression of vFLIP and phenotype of transformed cells.
The
transcription of the mRNA encoding vFLIP was confirmed by RT-PCR
from infected OMK cells, S. oedipus ex vivo-cultured T-cell
lines, and transformed human CBL-derived T-cell lines. Oligonucleotides
flanking the deleted region were chosen that generated PCR
amplification products of 266 bp from C488
FLIP and 531 bp from C488.
Contamination of the reactions resulting from genomic viral DNA was
ruled out by DNase I treatment and by analysis of an identically
treated parallel sample in which the reverse transcriptase was omitted
from the first-strand cDNA synthesis reaction. Fragments of the
expected sizes were amplified and confirmed the transcription of
herpesvirus saimiri vFLIP in C488-transformed and -infected cells and
the transcript that includes the deletion in C488
FLIP-infected cells
(Fig. 4). The amplified region also
encloses the 3' region of the vCyclin gene. However, by using several
different sets of oligonucleotide primers, no amplification products
corresponding to transcripts originating at the amino terminus of ORF73
that would be spliced to the vFLIP or vCyclin gene were detected (data
not shown). In addition, the surface phenotype of the transformed cells
was determined. We analyzed the transformed human CBL-derived and the
simian tumor-derived T-cell lines from all animals and could not detect
significant and consistent differences in the expression of cell
surface markers. An example shows CD3, CD4, and CD8 expression on C488
or the C488
FLIP deletion virus-transformed cells (Fig.
5). At least four different lymphoid cell
lines were established from each of the three animals; they showed no
significant variation in growth in cell culture, and all were
CD3+ T cells, with some variation in CD4 and CD8 expression
also within cell lines established from the same animal. Presumably,
during cultivation an initially polyclonal culture becomes
nonhomogenous due to the outgrowth of subclones. All cells
expressed surface markers which are typically found on mature activated
T cells, like CD2, CD3, CD4 and/or CD8, HLA-DR, CD80, or CD86,
but not B-cell markers like CD20 (data not shown).
|
|
Protection from apoptosis induced by FasL.
The surface
expression of the death receptor Fas-CD95 in the different simian and
human cell lines was studied by fluorescence-activated cell sorter
analysis. The results of an experiment with transformed T cells
obtained from the thymus of animals B236 (C488) and R213 (C488
FLIP)
are shown in Fig. 6, and Jurkat cells
served as a positive control. The CD95 surface marker was detectable on
both wild-type virus C488 or C488
FLIP transformed cells (Fig. 6).
|
FLIP-EGFP) viruses to discriminate infected from uninfected
cells. The herpesvirus saimiri-infected cells are easily identified by the green autofluorescence of EGFP when examined with
a fluorescein isothiocyanate-compatible filter set. The FasL-induced apoptosis was detectable in the OMK cells by nuclear
fragmentation that was visualized by the DNA binding dye Hoechst-33342.
A smaller proportion of green C488-infected cells seemed to show
nuclear fragmentation than the C488
FLIP-EGFP-infected cells;
however, an exact quantification was difficult due to concurrent lytic replication of the virus (data not shown). The
antiapoptotic effect of herpesvirus saimiri was then
analyzed in a system that quantifies apoptotic events.
Endogenous endonucleases are activated in apoptotic cells and
cleave the DNA into small oligonucleosomes containing histone
H1. These nucleosomal DNA fragments leak through the impaired nuclear membranes into the cytoplasm and are detected in cytoplasmatic extracts by the Cell Death Detection ELISA system. When
apoptosis was induced by superinfection with a
recombinant adenovirus expressing soluble FasL, an
antiapoptotic effect was detectable in
C488EGFP-infected OMK cells and not in C488
FLIP-EGFP-infected
cells. The results of four independent experiments are shown in Fig.
7A. In contrast to the observations of
OMK cells, the proliferation of transformed T cells (S. oedipus) was not affected by treatment with up to 1 µg soluble
FasL per ml. For comparison, Jurkat T cells are highly susceptible to 20-fold-lower doses of soluble FasL. Thus, a protective effect was not detectable, presumably due to overall resistance of the transformed T cells. Only the Fas-independent
proapoptotic substance menadione induced a decrease in
proliferation in both cells transformed with the wild-type virus C488
and those transformed with the deletion mutant virus C488
FLIP (Fig.
7B).
|
| |
DISCUSSION |
|---|
|
|
|---|
Herpesvirus saimiri is the prototype of the gamma-2 herpesviruses or Rhadinoviridae (1). It is apathogenic in the persistently infected natural host, the squirrel monkey (Saimiri sciureus), but causes rapidly progressive T-cell leukemia and lymphoma in several species of New World primates (22). Strains of the highly oncogenic subgroup C are capable of transforming primary human T cells to permanent antigen-independent growth (6), while subgroup A and B strains do not transform human cells. The herpesvirus saimiri genome (M-DNA) has a size of about 155 to 160 kb; it consists of a 113-kb AT-rich unique region (L-DNA) that is flanked by about 20 to 25 GC-rich, tandem repeats of 1.4 kb (H-DNA). This principal genome structure is shared by all rhadinoviruses except equine herpesvirus 2. Within the L-DNA region, herpesvirus saimiri has at least 76 ORFs plus genes for small nuclear URNAs, termed HSURs. The H-DNA terminal repeats of herpesvirus saimiri do not encode any known viral proteins (1). At the very left end of the L-DNA, all herpesvirus saimiri subgroups encode the saimiri transformation-associated proteins (STP-A, -B, or -C), a family of weakly conserved oncoproteins that are essential for the transformation of T cells and pathogenicity (12, 16, 33). The subgroup C strains additionally encode the tyrosine kinase-interacting protein, TIP, in this region, which is also essential for transformation (17). The HSURs are encoded in the region adjacent to the transforming genes; they are expressed in transformed cells but are dispensable for transformation in vitro (18). In addition to conserved gammaherpesvirus genes, herpesvirus saimiri shares several ORFs carrying sequestered cellular genes with the other rhadinoviruses KSHV/HHV8 and RRV, namely the vFLIP gene (ORF71), a vCyclin gene (ORF72), and a viral G protein-coupled receptor gene (ORF74, IL-8 receptor) (44). Recombinant herpesvirus saimiri has further been used to study the putative transforming protein K1 of KSHV/HHV8 (38) and is a useful model for gammaherpesvirus oncogenesis (32). RRVs are the closest relatives of KSHV/HHV8 (2, 50). Like herpesvirus saimiri, the RRVs do not seem to be tumorigenic in the natural host (39), and a lytic cell culture system in primary rhesus fibroblasts would allow the construction of recombinant viruses (13). However, no RRV-associated tumor or in vitro transformation model has been described so far.
Epidemiological data as well as the consistent detection of viral DNA in diseased tissue suggest that KSHV/HHV8 is most likely the major cofactor for the development of both classical KS and KS in immune response-compromised patients. In addition, KSHV/HHV8 is linked to several rare B-cell lymphoproliferative diseases, like primary effusion lymphoma (PEL) and multicentric Castleman's disease (27, 41). Although several reports hint at the possibility for the propagation of KSHV/HHV8 in cells derived from human endothelium or kidney (23, 42, 46), there is no accessible experimental model for the generation of recombinant viruses. Furthermore, there exist neither in vitro transformation models that involve the complete KSHV/HHV8 virus nor animal models for pathogenesis, e.g., for the development of KS- or PEL-like disease after viral infection.
Interestingly, the vFLIP- and vCyclin-encoding mRNA is found latently transcribed in KS in situ (51) and in KS and PEL by Northern blotting (14, 48, 49, 52, 53). The presence of a latent bicistronic mRNA encoding vFLIP and vCyclin, as well as a latent tricistronic mRNA encoding vFLIP, vCyclin, and the latency-associated nuclear antigen LANA in diseased tissue from KS and MCD hint at a role in progression or maintenance of the disease state by the inhibition of tumor cell apoptosis. vFLIP may also be required to counteract putative proapoptotic functions of the vCyclin gene under specific circumstances where high levels of cyclin-dependent kinase 6 are present in infected cells (45). Similarly, the KSHV/HHV8 LANA has been shown to exert an antiapoptotic function by inhibition of p53 transcriptional activity and thus promote cell survival (25). In contrast to the cultures established from KSHV/HHV8-associated PEL, where a small proportion of cells always produce viral particles and where the lytic cycle can be induced by stimulation with phorbol esters or sodium butyrate, the herpesvirus saimiri-transformed human T cells harbor the viral episomes in a latent state, and no infectious virus is produced even upon stimulation. We demonstrate that the ORF encoding vFLIP is transcribed in simian and human T cells transformed by herpesvirus saimiri (Fig. 4). However, vFLIP protein expression has not been published for KSHV/HHV8-associated tumors, and the protein was not detectable from our herpesvirus saimiri-transformed cell lines or other infected cells by immunoblot analysis with specific rabbit antisera (data not shown).
The antiapoptotic effect observed in the C488
wild-type virus-infected OMK cells was no longer detectable in
the C488
FLIP deletion virus-infected cells (Fig. 7B). However,
the fact that the herpesvirus saimiri vFLIP gene deletion reverses the
protective effect of herpesvirus saimiri C488 in OMK cells does not
rule out a relevant antiapoptotic function of the vBcl2
homolog. It may be that a missing balance to a potentially
proapoptotic vCyclin masks vBcl2 effects. However, this could
only be studied effectively if vBcl2 deletion viruses were available as well.
On one hand, induction of apoptosis by herpesvirus proteins,
including homologs of cellular regulators of apoptosis, has
been postulated as a way for more-efficient release of progeny virions from the infected cell and for the elimination of immune cells attacking the virus host cell. An example for herpesvirus
proapoptotic proteins is the induction of apoptosis in
mononuclear cells and bovine B-lymphoma BL-3 cells after binding of
bovine herpesvirus 1 glycoprotein D (29). Herpes simplex
virus type 1 (HSV-1) induces and blocks apoptosis at multiple
steps during infection and protects cells from exogenous inducers
in a cell type-dependent manner (26), and
ICP27-deleted HSV-1 induces apoptosis in epithelial cells
(4). HSV-2 induces apoptosis of macrophages in a
Fas- and TNFR-independent manner (21). On the other hand,
premature host cell destruction may be induced by the activation of
cellular signaling and apoptotic pathways. Such signals could
result from upregulation of surface receptor molecules, cytokine
secretion by infected cells, increased production of death receptor
ligands, or from endogenous events, e.g., those related to the p53 or
NF-
B pathways. vFLIP genes could interfere with some of these
events, and antiapoptotic gene expression in lytically
infected cells could result in a more-efficient production of progeny
virions. Although we speculated that a vFLIP deletion virus would be
impaired during lytic replication, no significant difference in virus
endpoint titer or viral replication kinetics was detectable (Fig. 2).
Thus, the herpesvirus saimiri vFLIP does not increase viral particle yield under the conditions of lytic tissue culture in OMK cells, the
standard cell line for propagation of herpesvirus saimiri (19).
Inhibition of death receptor-mediated apoptosis is a common
mechanism exploited by several DNA viruses to protect infected cells
from immune system attack by cytotoxic T cells. Adenovirus E3-14.5 and
E3-10.4 proteins are inhibitors of death receptor internalization. The
vFLIP proteins interfere with death receptor signal transduction, and
cowpox virus CrmA, baculovirus p35, and Ad E3-14.7 proteins have been
identified as downstream inhibitors of cellular caspases (reviewed
by Roulston and colleagues [47]). Several studies
suggest that the herpesvirus and cellular FLIPs act as putative tumor
progression factors in vitro and in tumor models based on the
introduction of FLIP-transduced cell lines in mice; they provide
evidence that tumor progression is in fact mediated by resistance to
T-cell-induced death receptor-mediated apoptosis (15,
40). Our data obtained with the C488
FLIP deletion mutant
cannot support the view that the herpesvirus saimiri vFLIP is a
cofactor for oncogenesis. There was no difference in the efficiency of
viral transformation in vitro; nor was there a significantly different
incubation period of herpesvirus saimiri disease in cottontop tamarins
(Table 1). There may be small differences in incubation time or disease
progression that might be detectable by titration of the pathogenic
viruses in the highly susceptible tamarins.
We also could not detect a significant difference in proliferation
between T cells transformed by herpesvirus saimiri C488 or C488
FLIP
(Fig. 7B). The postulated protective effect of vFLIP may be too
discrete to be detected in transformed T cells, since herpesvirus
saimiri-transformed human and simian T cells are rather resistant to
Fas-mediated apoptosis (37). However, this
resistance is not due to lack of death receptor expression, since
significant levels of Fas-CD95 are detectable on the transformed T
cells (Fig. 6). Moreover, a balanced expression and/or interaction
of Fas-FasL may promote T-cell growth, resulting in a net growth of the
culture, along with some apoptosis in fewer cells than those
replenished by expansion (34).
The ORF carrying the vFLIP gene of herpesvirus saimiri is transcribed in virus-infected and -transformed cells, and the antiapoptotic effect found after infection of OMK cells by herpesvirus saimiri C488 is reversed by deletion of the vFLIP gene. Thus, an antiapoptotic effect can be attributed to the vFLIP gene expression in virus-infected cells. However, in the herpesvirus saimiri system which allows testing of rhadinovirus transformation and pathogenesis, the deletion of the vFLIP gene did not affect transformation or oncogenicity. This may have implications for KSHV/HHV8-associated disease, since the vFLIP gene is also latently transcribed in cells persistently infected by KSHV/HHV8.
In principle, the vFLIPs may have evolved to counteract T-cell-mediated apoptosis of persistently infected cells in the natural host or to compensate for proapoptotic signals provided by other viral proteins like envelope glycoproteins or vCyclin. The latter is an attractive hypothesis: the growth-promoting vCyclin is expressed from the same bi- or polycistronic message that also encodes vFLIP, and the vCyclin of KSHV/HHV8 has been shown to promote apoptosis in transfected cells that have entered S phase (45). High levels of the vFLIP and vCyclin message are detectable in advanced lesions of KS (51). In this model, vFLIP would not offer protection from externally induced apoptosis but would balance proapoptotic stimuli associated with the growth promoting functions of the virus itself. Although the similar domain structure and conserved genomic context, as well as in vitro data obtained from overexpression studies in transfected cell lines, suggest an analogous function, it still may be that the vFLIPs of KSHV/HHV8 and herpesvirus saimiri play different roles in their respective target tissues in vivo, and the vFLIP of KSHV may be essential for the transformation by KSHV, in contrast to herpesvirus saimiri. However, rhadinoviruses usually cause either minor or no relevant pathology in their natural host. Since we do not find herpesvirus saimiri vFLIP relevant to viral transformation or pathogenesis, we speculate that vFLIP expression may result in improved survival of acutely or persistently infected or transformed cells and may consequently enlarge or maintain the cellular reservoir for viruses in the persistently infected natural host.
| |
ACKNOWLEDGMENTS |
|---|
We thank Martina Göen and Monika Schmidt for their excellent technical assistance and Helmut Fickenscher and Jürg Tschopp for reagents.
This work was supported by the Deutsche Forschungsgemeinschaft, Sonderforschungsbereich 466, Lymphoproliferation und Immundefizienz.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institut für Klinische und Molekulare Virologie der Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany. Phone: 49-9131-8523786. Fax: 49-9131-851002. E-mail: ensser{at}viro.med.uni-erlangen.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Albrecht, J. C.,
J. Nicholas,
D. Biller,
K. R. Cameron,
B. Biesinger,
C. Newman,
S. Wittmann,
M. A. Craxton,
H. Coleman,
B. Fleckenstein, and R. W. Honess.
1992.
Primary structure of the herpesvirus saimiri genome.
J. Virol.
66:5047-5058 |
| 2. |
Alexander, L.,
L. Denekamp,
A. Knapp,
M. R. Auerbach,
B. Damania, and R. C. Desrosiers.
2000.
The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577.
J. Virol.
74:3388-3398 |
| 3. |
Ashkenazi, A., and V. M. Dixit.
1998.
Death receptors: signaling and modulation.
Science
281:1305-1308 |
| 4. |
Aubert, M.,
J. O'Toole, and J. A. Blaho.
1999.
Induction and prevention of apoptosis in human HEp-2 cells by herpes simplex virus type 1.
J. Virol.
73:10359-10370 |
| 5. |
Bertin, J.,
R. C. Armstrong,
S. Ottilie,
D. A. Martin,
Y. Wang,
S. Banks,
G. H. Wang,
T. G. Senkevich,
E. S. Alnemri,
B. Moss,
M. J. Lenardo,
K. J. Tomaselli, and J. I. Cohen.
1997.
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis.
Proc. Natl. Acad. Sci. USA
94:1172-1176 |
| 6. |
Biesinger, B.,
I. Müller-Fleckenstein,
B. Simmer,
G. Lang,
S. Wittmann,
E. Platzer,
R. C. Desrosiers, and B. Fleckenstein.
1992.
Stable growth transformation of human T lymphocytes by herpesvirus saimiri.
Proc. Natl. Acad. Sci. USA
89:3116-3119 |
| 7. | Bruder, J. T., A. Appiah, W. M. Kirkman III, P. Chen, J. Tian, D. Reddy, D. E. Brough, A. Lizonova, and I. Kovesdi. 2000. Improved production of adenovirus vectors expressing apoptotic transgenes. Hum. Gene Ther. 11:139-149[CrossRef][Medline]. |
| 8. | Chaudhary, P. M., A. Jasmin, M. T. Eby, and L. Hood. 1999. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18:5738-5746[CrossRef][Medline]. |
| 9. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159[Medline]. |
| 10. |
Dear, S., and R. Staden.
1991.
A sequence assembly and editing program for efficient management of large projects.
Nucleic Acids Res.
19:3907-3911 |
| 11. |
Derfuss, T.,
H. Fickenscher,
M. S. Kraft,
G. Henning,
D. Lengenfelder,
B. Fleckenstein, and E. Meinl.
1998.
Antiapoptotic activity of the herpesvirus saimiri-encoded Bcl-2 homolog: stabilization of mitochondria and inhibition of caspase-3-like activity.
J. Virol.
72:5897-5904 |
| 12. |
Desrosiers, R. C.,
R. L. Burghoff,
A. Bakker, and J. Kamine.
1984.
Construction of replication-competent herpesvirus saimiri deletion mutants.
J. Virol.
49:343-348 |
| 13. | Desrosiers, R. C., V. G. Sasseville, S. C. Czajak, X. Zhang, K. G. Mansfield, A. Kaur, R. P. Johnson, A. A. Lackner, and J. U. Jung. 1997. A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J. Virol. 71:9764-9769[Abstract]. |
| 14. |
Dittmer, D.,
M. Lagunoff,
R. Renne,
K. Staskus,
A. Haase, and D. Ganem.
1998.
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus.
J. Virol.
72:8309-8315 |
| 15. |
Djerbi, M.,
V. Screpanti,
A. I. Catrina,
B. Bogen,
P. Biberfeld, and A. Grandien.
1999.
The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors.
J. Exp. Med.
190:1025-1032 |
| 16. |
Duboise, M.,
J. Guo,
S. Czajak,
H. Lee,
R. Veazey,
R. C. Desrosiers, and J. U. Jung.
1998.
A role for herpesvirus saimiri orf14 in transformation and persistent infection.
J. Virol.
72:6770-6776 |
| 17. |
Duboise, S. M.,
J. Guo,
S. Czajak,
R. C. Desrosiers, and J. U. Jung.
1998.
STP and Tip are essential for herpesvirus saimiri oncogenicity.
J. Virol.
72:1308-1313 |
| 18. |
Ensser, A.,
A. Pfinder,
I. Müller-Fleckenstein, and B. Fleckenstein.
1999.
The URNA genes of herpesvirus saimiri (strain C488) are dispensable for transformation of human T cells in vitro.
J. Virol.
73:10551-10555 |
| 19. | Falk, L. A. 1980. Biology of herpesvirus saimiri and herpesvirus ateles, p. 813-833. In G. Klein (ed.), Viral oncology. Raven Press, New York, N.Y. |
| 20. | Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6-13[CrossRef][Medline]. |
| 21. | Fleck, M., J. D. Mountz, H. C. Hsu, J. Wu, C. K. Edwards III, and E. R. Kern. 1999. Herpes simplex virus type 2 infection induced apoptosis in peritoneal macrophages independent of Fas and tumor necrosis factor-receptor signaling. Viral Immunol. 12:263-275[Medline]. |
| 22. | Fleckenstein, B., and R. C. Desrosiers. 1982. Herpesvirus saimiri and herpesvirus ateles, p. 253-332. In B. Roizman (ed.), The herpesviruses, vol. 1. Plenum Press, New York, N.Y. |
| 23. | Flore, O., S. Rafii, S. Ely, J. J. O'Leary, E. M. Hyjek, and E. Cesarman. 1998. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 394:588-592[CrossRef][Medline]. |
| 24. |
French, L. E., and J. Tschopp.
1999.
Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors.
J. Exp. Med.
190:891-894 |
| 25. | Friborg, J., Jr., W. Kong, M. O. Hottiger, and G. J. Nabel. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889-894[Medline]. |
| 26. |
Galvan, V., and B. Roizman.
1998.
Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner.
Proc. Natl. Acad. Sci. USA
95:3931-3936 |
| 27. | Ganem, D. 1998. Human herpesvirus 8 and its role in the genesis of Kaposi's sarcoma. Curr. Clin. Top. Infect. Dis. 18:237-251[Medline]. |
| 28. |
Guo, J.,
K. Williams,
S. M. Duboise,
L. Alexander,
R. Veazey, and J. U. Jung.
1998.
Substitution of ras for the herpesvirus saimiri STP oncogene in lymphocyte transformation.
J. Virol.
72:3698-3704 |
| 29. | Hanon, E., G. Keil, S. Drunen Littel-van den Hurk, P. Griebel, A. Vanderplasschen, F. A. Rijsewijk, L. Babiuk, and P. P. Pastoret. 1999. Bovine herpesvirus 1-induced apoptotic cell death: role of glycoprotein D. Virology 257:191-197[CrossRef][Medline]. |
| 30. |
Hu, S.,
C. Vincenz,
M. Buller, and V. M. Dixit.
1997.
A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis.
J. Biol. Chem.
272:9621-9624 |
| 31. | Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195[CrossRef][Medline]. |
| 32. | Jung, J. U., J. K. Choi, A. Ensser, and B. Biesinger. 1999. Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Semin. Cancer Biol. 9:231-239[CrossRef][Medline]. |
| 33. |
Jung, J. U.,
J. J. Trimble,
N. W. King,
B. Biesinger,
B. W. Fleckenstein, and R. C. Desrosiers.
1991.
Identification of transforming genes of subgroup A and C strains of herpesvirus saimiri.
Proc. Natl. Acad. Sci. USA
88:7051-7055 |
| 34. |
Kennedy, N. J.,
T. Kataoka,
J. Tschopp, and R. C. Budd.
1999.
Caspase activation is required for T cell proliferation.
J. Exp. Med.
190:1891-1896 |
| 35. |
Knappe, A.,
C. Hiller,
H. Niphuis,
F. Fossiez,
M. Thurau,
S. Wittmann,
E. M. Kuhn,
S. Lebecque,
J. Banchereau,
B. Rosenwirth,
B. Fleckenstein,
J. Heeney, and H. Fickenscher.
1998.
The interleukin-17 gene of herpesvirus saimiri.
J. Virol.
72:5797-5801 |
| 36. |
Knappe, A.,
M. Thurau,
H. Niphuis,
C. Hiller,
S. Wittmann,
E. M. Kuhn,
B. Rosenwirth,
B. Fleckenstein,
J. Heeney, and H. Fickenscher.
1998.
T-cell lymphoma caused by herpesvirus saimiri C488 independently of ie14/vsag, a viral gene with superantigen homology.
J. Virol.
72:3469-3471 |
| 37. |
Kraft, M. S.,
G. Henning,
H. Fickenscher,
D. Lengenfelder,
J. Tschopp,
B. Fleckenstein, and E. Meinl.
1998.
Herpesvirus saimiri transforms human T-cell clones to stable growth without inducing resistance to apoptosis.
J. Virol.
72:3138-3145 |
| 38. | Lee, H., R. Veazey, K. Williams, M. Li, J. Guo, F. Neipel, B. Fleckenstein, A. Lackner, R. C. Desrosiers, and J. U. Jung. 1998. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat. Med. 4:435-440[CrossRef][Medline]. |
| 39. |
Mansfield, K. G.,
S. V. Westmoreland,
C. D. DeBakker,
S. Czajak,
A. A. Lackner, and R. C. Desrosiers.
1999.
Experimental infection of rhesus and pig-tailed macaques with macaque rhadinoviruses.
J. Virol.
73:10320-10328 |
| 40. |
Medema, J. P.,
J. de Jong,
T. van Hall,
C. J. Melief, and R. Offringa.
1999.
Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.
J. Exp. Med.
190:1033-1038 |
| 41. | Moore, P. S., and Y. Chang. 1998. Antiviral activity of tumor-suppressor pathways: clues from molecular piracy by KSHV. Trends Genet. 14:144-150[CrossRef][Medline]. |
| 42. |
Moses, A. V.,
K. N. Fish,
R. Ruhl,
P. P. Smith,
J. G. Strussenberg,
L. Zhu,
B. Chandran, and J. A. Nelson.
1999.
Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8.
J. Virol.
73:6892-6902 |
| 43. | Nava, V. E., E. H. Y. Cheng, M. Veliuona, S. Zou, R. J. Clem, M. L. Mayer, and J. M. Hardwick. 1997. Herpesvirus saimiri encodes a functional homolog of the human bcl-2 oncogene. J. Virol. 71:4118-4122[Abstract]. |
| 44. |
Neipel, F.,
J. C. Albrecht, and B. Fleckenstein.
1998.
Human herpesvirus 8 the first human rhadinovirus.
J. Natl. Cancer Inst. Monogr.
23:73-77.
|
| 45. |
Ojala, P. M.,
M. Tiainen,
P. Salven,
T. Veikkola,
V. E. Castanos,
R. Sarid,
P. Biberfeld, and T. P. Makela.
1999.
Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.
Cancer Res.
59:4984-4989 |
| 46. |
Renne, R.,
D. Blackbourn,
D. Whitby,
J. Levy, and D. Ganem.
1998.
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells.
J. Virol.
72:5182-5188 |
| 47. | Roulston, A., R. C. Marcellus, and P. E. Branton. 1999. Viruses and apoptosis. Annu. Rev. Microbiol. 53:577-628[CrossRef][Medline]. |
| 48. |
Sarid, R.,
O. Flore,
R. A. Bohenzky,
Y. Chang, and P. S. Moore.
1998.
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).
J. Virol.
72:1005-1012 |
| 49. |
Sarid, R.,
J. S. Wiezorek,
P. S. Moore, and Y. Chang.
1999.
Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter.
J. Virol.
73:1438-1446 |
| 50. |
Searles, R. P.,
E. P. Bergquam,
M. K. Axthelm, and S. W. Wong.
1999.
Sequence and genomic analysis of a rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.
J. Virol.
73:3040-3053 |
| 51. |
Stürzl, M.,
C. Hohenadl,
C. Zietz,
V. E. Castanos,
A. Wunderlich,
G. Ascherl,
P. Biberfeld,
P. Monini,
P. J. Browning, and B. Ensoli.
1999.
Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells.
J. Natl. Cancer Inst.
91:1725-1733 |
| 52. |
Sun, R.,
S. F. Lin,
K. Staskus,
L. Gradoville,
E. Grogan,
A. Haase, and G. Miller.
1999.
Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.
J. Virol.
73:2232-2242 |
| 53. | Talbot, S. J., R. A. Weiss, P. Kellam, and C. Boshoff. 1999. Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology 257:84-94[CrossRef][Medline]. |
| 54. | Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J. L. Bodmer, M. Schroter, C. Scaffidi, P. H. Krammer, M. E. Peter, and J. Tschopp. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521[CrossRef][Medline]. |
| 55. | Wang, G. H., J. Bertin, Y. Wang, D. A. Martin, J. Wang, K. J. Tomaselli, R. C. Armstrong, and J. I. Cohen. 1997. Bovine herpesvirus 4 BORFE2 protein inhibits Fas- and tumor necrosis factor receptor 1-induced apoptosis and contains death effector domains shared with other gamma-2 herpesviruses. J. Virol. 71:8928-8932[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»